MedTrace Logo

Dose-dEscalated MR-Guided Radiotherapy for Localized Prostate Cancer

NCT07674225 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-09-03

No results posted yet for this study

Summary

DESTINATION 2 is a multi-centre randomised trial treating intermediate risk localised prostate cancer with 2 fraction Stereotactic Body Radiotherapy (SBRT). All radiotherapy will be delivered in two fractions (sessions) on an MR Linac using daily adaptation. Men will either receive uniform dose radiotherapy or de-escalated dose radiotherapy. The primary endpoint is acute GU CTCAE v5 grade 2+ toxicity. It will also look at late toxicity, patient-reported outcome measures and PSA control.

Conditions

Interventions

RADIATION

Prostate radical radiotherapy

All radiotherapy will be delivered in two fractions (sessions) on an MR Linac using daily adaptation.

RADIATION

Prostate radical radiotherapy

All radiotherapy will be delivered in two fractions (sessions) on an MR Linac using daily adaptation

Sponsors & Collaborators

  • Elekta Limited

    collaborator INDUSTRY

  • MRL Consortium

    collaborator UNKNOWN

  • Sunnybrook Health Sciences Centre

    lead OTHER

Principal Investigators

  • Dr. Danny Vesprini, MSc, MD, FRCPC · Sunnybrook Odette Cancer Centre, University of Toronto

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-22
Primary Completion
2028-06-01
Completion
2030-06-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07674225 on ClinicalTrials.gov